Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. - Wikidata - awgldk - TriplyDB

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

http://www.wikidata.org/entity/Q37411669

about

The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemia Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Progress in acute myeloid leukemia A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature.Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia The treatment of elderly patients with acute myeloid leukemia.Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Anthracycline dose intensification in young adults with acute myeloid leukemia.N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia Acute myeloid leukaemia: optimal management and recent developments.Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis.Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.Chemotherapy options for previously untreated acute myeloid leukemia.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia.Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia.Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Improved Survival With Integration of Chinese Herbal Medicine Therapy in Patients With Acute Myeloid Leukemia: A Nationwide Population-Based Cohort Study.Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.Barriers to the Collaboration Between Hematologists and Palliative Care Teams on Relapse or Refractory Leukemia and Malignant Lymphoma Patients' Care: A Qualitative Study.Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia.

P2860

Q24187297-0FE2556C-5BD5-4445-BA40-A037E3F996E0 Q24200224-93787132-559C-4243-9BB4-FC0B4ABBEE32 Q24200407-8B8E6172-CD31-4FAF-B07F-7869A3DEBA74 Q26799609-76500275-4A77-43B9-9242-6F4C661C7D67 Q27024006-7B69F254-EC70-4336-B2A3-1E2CB27391F3 Q27684428-B58A1906-B682-41AD-9CAD-26478B31DD9C Q30251621-EAECF0C0-18BC-4F6D-9CC7-21D1AE32DC6D Q33841129-6F5A1766-1329-4FE3-95A7-EBDE3BE17992 Q33949752-30871B6A-0136-40E4-8EAC-451F2CBD737E Q34673820-C1811A1E-AFC3-4E3B-B100-66D5219971C8 Q35085867-79FECF44-A28A-4B4D-9B5C-0EB57912F964 Q35673578-E54D4743-7496-4C26-A66C-CCA987427D85 Q35717841-D1C22BDD-8C29-4CC1-A114-3991B24AD2E3 Q35859437-BA530270-7BFB-42B0-A67B-6C45AAADDC7A Q35944724-A23C7DA2-7BB7-4DA6-91F0-779F13E65F22 Q36053792-F8A1E2E7-4E62-4E23-9EB2-CA5287521FDC Q36612663-ADF0FB55-44E7-4516-B122-993348D8B0F6 Q36722841-13DC98A3-22E4-459D-AF0F-2BAD539C0CC2 Q36914091-AD068B29-03CF-44A9-A101-6B262BEDAD28 Q37026715-3B2242AB-F557-485A-A478-6ABA97A93F4C Q37289691-2A9C89B6-78D1-4998-A5E5-DCEFFB07D727 Q37323006-32D7E2AD-5AA4-41B5-9FD2-1B32B42A7269 Q37364509-9725D47F-CF3D-4BC7-88F2-E69C853C49D6 Q37851038-3506E7E9-DCEA-401D-A5F0-E741B5C11EBA Q38080583-F12470A3-C44F-41E2-9F3C-DF94BB3D5756 Q38270780-E148791F-33A8-48B7-B09A-A170DDD16E6D Q38585930-0C5DD0C8-1774-4CA5-970C-D6C016ACB7DC Q38644941-4A178AA7-8051-4CAC-BFF9-03CF1C57A4E9 Q38664735-3D269E70-CD0F-4B5B-A669-B62256D4DF4D Q38757179-1847D4F6-3E54-420D-A203-D6EB1ED850A8 Q38916984-7B7E7038-4943-4654-B0D0-7C040FBB1D43 Q39092515-E5D6B055-6E40-49FB-BDC2-E5E127048998 Q39116969-6BD0C6C5-0815-4F51-97E6-A7572F6142B1 Q39135512-19CE2525-7AB2-44B6-A6E4-EB2006591B14 Q39374988-E4CC9D55-C72A-43EE-B782-02F75298CA89 Q39416207-C84A29FB-F4B0-4EBE-A108-36A3E21CBBDD Q39483755-263B0920-9895-4166-9607-3A364687B05F Q40256523-B0A57D6D-2F1A-4B77-8A9B-00989109EF56 Q40400225-36239F16-9DEF-4FCC-AE33-E0FD5F395C48 Q41225917-4888194E-C596-447E-8A4F-D9DEEEF2E4B1

P2860

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

http://www.wikidata.org/entity/Q37411669

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@en

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@nl

type

label

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@en

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@nl

prefLabel

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@en

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@nl

P1433

Q37411669-83DCD09B-DE35-4B40-80E0-C257B70960DB

P1476

Q37411669-7F8784A6-D097-4957-9A25-8804DB2F0C23

P2093

Q37411669-045FE4CE-7EA8-4C3E-A778-05752DC7FEF7

Q37411669-097AADBB-D3F2-4FED-B2A5-A7EC78C7C69E

Q37411669-1539483D-9422-4EE3-A4C8-3A893E858313

Q37411669-171CF661-D383-4C49-8890-588ED7BD5F8D

Q37411669-1C2BFA78-009B-42C8-83DC-34863532F5BB

Q37411669-2AEC5487-A068-4C86-B773-CAFF4667A96B

Q37411669-39C9A1A7-07FB-43F7-A255-FAB5DAF9DCAF

Q37411669-3F118FAA-3D0F-4341-AFF6-1C12259CE125

Q37411669-560D3B53-F5B4-4EF5-9C3C-25EDAA6DA7EB

Q37411669-647AFEFC-7B6C-4BA1-9062-81243D0AF19E

P2860

Q37411669-12E50539-6BB1-4B70-91FE-71618B643DE7

Q37411669-14D93A47-1A17-45D6-9C5F-9E12194BC2E6

Q37411669-18054474-3487-455D-8956-7BE9EEB65B0B

Q37411669-35912A77-CA0E-42A3-818A-8986C488D034

Q37411669-418A00E5-3AA9-4917-A091-97F51E591C43

Q37411669-475EEE1F-AF96-4989-A081-5BEEBC59229E

Q37411669-561A1021-AF72-4057-A6DC-E3E420FFAA3E

Q37411669-65F07A29-CDA6-471D-BC7A-C89F0D630E1C

Q37411669-6B158095-8094-4B48-83FA-F5622288C606

Q37411669-6E260E4C-1685-4AB0-AE72-647FCD655264

P304

Q37411669-7C29C61C-A6D7-4F56-A40A-A7138DEC8EDD

P31

Q37411669-21A94D08-46D8-4A20-B3E8-93DB4D44773C

P356

Q37411669-33143DEB-95AA-4B67-8E65-CCF0DD564BAB

P407

Q37411669-F4DDAE02-3615-4CA9-8EA0-F4CB586B425E

P433

Q37411669-97ED505C-0EB4-4C7C-B6DD-F7EBC7E32C77

P478

Q37411669-7827930D-C504-43C3-BD1B-2BD1F92575C6

P50

Q37411669-2D72F810-15A2-4C11-A6B9-CBF35377DBB8

P577

Q37411669-19D7EEDC-926F-47D1-8195-D55E559018DD

P5875

Q37411669-8C2E4277-A2B4-44B4-947F-60A6F55211A4

P698

Q37411669-D321EF6A-7D1A-4331-A849-C2196735D66A

P921

Q37411669-5B71F4CB-42D0-4FF3-864D-D3D0EEA5B9DA

Q37411669-F58CF826-7AA3-4F34-9718-59657A8BDDD7

P932

Q37411669-D1FA6B94-3AF7-4264-9134-E8C36836232F

P356

JCO.2008.20.6490

P1433

Journal of Clinical Oncology

P1476

Daunorubicin versus mitoxantro ...... nd GIMEMA Groups Study AML-10.

@en

P2093

Boris Labar

http://www.w3.org/2001/XMLSchema#string

Felicetto Ferrara

http://www.w3.org/2001/XMLSchema#string

Filippo Marmont

http://www.w3.org/2001/XMLSchema#string

Francesco Di Raimondo

http://www.w3.org/2001/XMLSchema#string

Franco Mandelli

http://www.w3.org/2001/XMLSchema#string

Giovanna Meloni

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Marie

http://www.w3.org/2001/XMLSchema#string

Liliana Baila

http://www.w3.org/2001/XMLSchema#string

Marco Vignetti

http://www.w3.org/2001/XMLSchema#string

Maria-Concetta Petti

http://www.w3.org/2001/XMLSchema#string

P2860

Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.

Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

Acute myeloid leukemia.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group.

Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz

P304

5397-5403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.6490

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26891744

http://www.w3.org/2001/XMLSchema#string

P698

19826132

http://www.w3.org/2001/XMLSchema#string

P921

P932

2773224

http://www.w3.org/2001/XMLSchema#string